I have been given a chance to participate in the camms224 trial. After carefully weighing up the potential risks and rewards I have decided to go for it. Campath is certainly at the extreme end of MS treatments with some pretty scary potential side effects, but the chance to potentially stop MS in its tracks is far too good to pass up whatever the risks.

I have to have a series of blood tests next ...

....and speaking of press articles, (weren't we somewhere? :wink: :D ), here is the one that the Bloomberg News did, after speaking with some of us. I believe, though, that they are continuing to follow this story as it all unfolds, and I'm pretty certain we haven't seen nor heard that last from them. (All in all, in ...

Given the hypotheses that MS may have a viral cause especially the Epstein Barr virus, I am going to discuss with my doctor taking valacyclovir which is an anti-viral treatment. In a 2002 study in Denmark patients on valacyclovir showed 20% fewer lesions on average than controls. Is anybody else trying this or contemplating this?


Alex, London

The real Elan tragedy

'My first reaction was panic,' said MS sufferer Wendy Sargent, who was participating in a Tysabri trial. The drug's withdrawal has raised question marks over the future of both the company and those who need it


John Mulligan

6 March, 2005, The Sunday Tribune


TYSABRI changed Wendy Sargent's life.

Before the 30-year-old Toronto native was diagnosed with Multiple Sclerosis in October 2001, she was missing weeks from work, feeling run ...

I've been reading some other message boards, and there is much discussion regarding all of the other medications that Tysabri clinical trial patients were taking along with Tysabri.

I have ONE question. Why in the world would you run a clinical trial on a medication that you aren't even sure how it works, how well it works, etc. by itself ALONE, and allow so many other drugs to be taken along with it? Especially with ...

.
Irish Sunday Post / Lars interview

Tysabri: The inside story

06 March 2005

On February 17, Elan and its partner, Biogen, announced promising results from a two-year trial on their multiple sclerosis (MS) drug, Tysabri.

Within days, they learned of a fatality and a second case of viral symptoms from patients using a combination of Tysabri and Biogen's Avonex drug.

Lars Ekman, head of research and development of Elan, talks about the countdown to ...

Just thought that this was something interesting to ponder. Co-administration of Avonex reduces Tysabri clearance by approximately 1/3rd. As you can see from the FDA label, Biogen/Elan did not think this would be a problem, but they did consider it... So not only may Avonex's immunomodulation combined with Tysabri's be too much, but Avonex's effect on Tysabri ALONE may boost T's immunosuppressive capabilities.

In other words, it's not just A+T we're looking at here, but ...

I've been debating with myself whether to post this quote that appeared on another MS forum. The person who posted it stated that it was obtained from the Biogen message board. I have no way of verifying this other than it appears to be legitimate.

I know it is going to instigate responses of various opinions but I hope everyone respects all the opinions expressed.

The original poster was quite upset by the fact that ...

This is a link to a VERY interesting article about Tysabri and what possibilities can take place when tinkering with the immune system.

http://www.businessweek.com/magazine/co ... _mz011.htm

Harry